Table 2.
Samples used for quantification and linearity studies.
| Study | Sample code | Sourcea | Strain name | Strain sequence ID (database) | sample stock (copies/mL)b |
|---|---|---|---|---|---|
| Quantification | dsDNA_ Ngene (gBlock) | IDT | n/a | n/a | 3.78E+13 |
| Clinical sample - 243 | HC | n/a | n/a | 1.4E+07 | |
| Linearity study | Clinical sample - 12 (ancestral lineage) | VdH | c | c | 4.96E+08 |
| Clinical sample - UK 7 (Alpha lineage) | VdH | hCoV-19/Spain/CT-HUVH-88240/2021 | EPI_ISL_954175 (GISAID) |
9.71E+07 | |
| WHO international standard | NIBSC | England/02/2020 | MW059036 (GenBank) | 1.42E+07 |
a
IDT: Integrated DNA Technologies (Coralville, IA, USA). HC: Hospital Clinic (Barcelona, Spain). VdH: Vall d'Hebron Hospital (Barcelona, Spain). NIBSC: National Institute for Biological Standards and Control (Blanche Lane, Ridge, Herts, UK), material code: 20/146.
b
Concentration of gBlock was calculated using Nanodrop and Molecular Weight of the sequence. Concentrations of clinical samples and World Health Organization International Standard were obtained during the Standard RT-qPCR curve optimization (sample 243) or quantification step.
c
Clinical sample 12 corresponds to a clinical sample collected at the beginning of the pandemic, corresponding to the ancestral lineage.